Stocks · News reference
Barclays Maintains Overweight on PTC Therapeutics, Raises Price Target to $122
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 14, 2026, 2:23 PM
- Checked
- Aug 14, 2026, 2:23 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
PTC Therapeutics Expands Rare Disease Portfolio with 'Unique Opportunity'
PTC Therapeutics plans to acquire Sangamo’s ST-920 Fabry disease program for $111 million upfront, with FDA filing expected in Q4 2026.
Read original at benzingaWells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $109
Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $106 to $109.
Read original at benzinga